Parkinson's disease affects around 153,000 people in the UK, according to Parkinson's UK, making it one of the most common neurological conditions community pharmacists encounter in their dispensing practice. The medicines used to manage it are effective but unforgiving: timing matters, interactions are clinically significant, and side effects can be distressing if patients are not properly counselled.

This guide covers the core pharmacology community pharmacists need, the counselling points that make the biggest practical difference, and the red flags that warrant urgent referral.

The medicines landscape

Parkinson's treatment centres on restoring dopaminergic activity in the brain. The main drug classes are:

NICE guideline NG71 recommends levodopa as the first-line treatment when motor symptoms affect quality of life. Dopamine agonists or MAO-B inhibitors may be offered initially when motor symptoms are mild, particularly in younger patients where delaying levodopa-related motor complications is a consideration.

Levodopa: the counselling points that matter

Levodopa is the most effective treatment but also the most timing-sensitive. Community pharmacists dispense it frequently and are well placed to reinforce critical points.

Timing and food. Levodopa competes with dietary amino acids for absorption in the small intestine. Patients should take standard-release preparations 30 to 60 minutes before meals, or at least one hour after eating. High-protein meals reduce absorption most significantly. Modified-release formulations (Sinemet CR, Madopar CR) have different pharmacokinetics and should not be crushed or chewed.

Dose timing is critical. Patients with advancing disease may take levodopa at precise intervals — sometimes as frequently as every two hours. A delayed dose can trigger an "off" period within 30 minutes. Pharmacists should emphasise that this is not a medicine where "roughly the right time" is acceptable. For patients using multiple daily doses, a medication alarm or reminder app is worth suggesting.

"On-off" fluctuations. As the disease progresses, patients experience wearing-off (symptoms returning before the next dose is due) and unpredictable "off" periods. If a patient reports these, the prescriber may add entacapone or switch to a combination preparation (Stalevo). Pharmacists should be alert to wearing-off complaints as a trigger for medication review.

Discolouration of bodily fluids. Levodopa can turn urine, sweat, and saliva dark. This is harmless but can alarm patients if they are not warned.

Dopamine agonists: impulse control disorders

Dopamine agonists carry a distinctive and serious counselling requirement: impulse control disorders (ICDs). These include pathological gambling, hypersexuality, compulsive shopping, and binge eating. NICE NG71 states that patients starting dopamine agonists must be warned about ICDs before treatment begins and monitored throughout.

The prevalence is not trivial. Studies suggest ICDs affect 13 to 46 per cent of patients on dopamine agonists, depending on the population studied and the screening tool used. Patients may not volunteer these symptoms due to embarrassment, so proactive questioning is important.

What pharmacists can do:

• Confirm at first dispensing that the patient has been counselled about ICDs
• Ask at repeat dispensing whether the patient or their family has noticed any changes in behaviour
• If an ICD is suspected, refer to the prescribing team — dose reduction or switching is usually required

The rotigotine transdermal patch (Neupro) carries the same ICD risk as oral dopamine agonists.

MAO-B and COMT inhibitors: interaction awareness

MAO-B inhibitors (rasagiline, selegiline, safinamide) inhibit monoamine oxidase type B selectively at therapeutic doses, but drug interactions remain clinically relevant:

• Serotonergic drugs: combining MAO-B inhibitors with SSRIs, SNRIs, tramadol, or pethidine carries a theoretical risk of serotonin syndrome. The BNF advises caution and, for some combinations, avoidance. Pharmacists should check new prescriptions for these combinations.
• Sympathomimetics: pseudoephedrine and phenylephrine (available OTC) should be avoided with MAO-B inhibitors due to the risk of hypertensive crisis.
• Tyramine: the "cheese reaction" is less relevant with selective MAO-B inhibitors at recommended doses, but patients on higher-than-licensed doses or selegiline should still be advised to moderate tyramine-rich foods.

COMT inhibitors extend levodopa's effect by blocking its peripheral metabolism. Entacapone is taken with every levodopa dose; opicapone is taken once daily at bedtime, at least one hour before or after levodopa. The most common side effect is diarrhoea. Entacapone also causes orange discolouration of urine — patients should be warned.

Medicines to avoid and OTC considerations

Several common medicines can worsen Parkinson's symptoms by blocking dopamine receptors:

When a patient with Parkinson's presents with nausea — whether from the disease itself or from levodopa — domperidone is the appropriate recommendation. Metoclopramide and prochlorperazine should never be supplied.

When to refer

Community pharmacists should refer patients urgently if they present with:

• Sudden inability to move ("freezing" episodes lasting more than a few minutes, or a marked deterioration from baseline)
• Neuroleptic malignant-like syndrome: fever, rigidity, and confusion in a patient whose Parkinson's medicines have been abruptly stopped — this is a medical emergency
• Falls: recurrent falls may indicate disease progression or postural hypotension from medication
• Hallucinations or psychosis: common in advanced Parkinson's, especially with dopamine agonists — requires specialist review
• Swallowing difficulties: may affect the ability to take oral medicines and indicates disease progression

Never abruptly stop Parkinson's medicines. This is a critical safety message. Sudden withdrawal of levodopa or dopamine agonists can precipitate a neuroleptic malignant-like syndrome, which is life-threatening. If a patient is nil by mouth (e.g. for surgery), the prescribing team must arrange alternative routes of administration.

The pharmacy role in Parkinson's care

Community pharmacists see Parkinson's patients regularly — often more frequently than their neurologist. The New Medicine Service provides a structured framework for supporting patients starting levodopa or dopamine agonists. Structured Medication Reviews offer an opportunity to identify wearing-off, ICDs, or problematic drug interactions.

According to PharmSee's tracker, there are currently 1,715 active pharmacy vacancies across England, including roles in community, hospital, and primary care settings where Parkinson's medicines management is a core competency. For pharmacists interested in specialist neurology roles, NHS Jobs listings occasionally include positions in movement disorder clinics and Parkinson's specialist pharmacy.

Sources

• NICE guideline NG71: Parkinson's disease in adults (2017, updated 2024)
• Parkinson's UK: statistics and prevalence data
• BNF: individual drug monographs for levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors
• MHRA: safety advice on dopamine agonists and impulse control disorders
• PharmSee vacancy tracker: 1,715 active roles as of 15 April 2026